Last reviewed · How we verify
Multivalent plain polysaccharide vaccine — Competitive Intelligence Brief
phase 1
Biologic
Live · refreshed every 30 min
Target snapshot
Multivalent plain polysaccharide vaccine (Multivalent plain polysaccharide vaccine) — LimmaTech Biologics AG.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Multivalent plain polysaccharide vaccine TARGET | Multivalent plain polysaccharide vaccine | LimmaTech Biologics AG | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Multivalent plain polysaccharide vaccine CI watch — RSS
- Multivalent plain polysaccharide vaccine CI watch — Atom
- Multivalent plain polysaccharide vaccine CI watch — JSON
- Multivalent plain polysaccharide vaccine alone — RSS
Cite this brief
Drug Landscape (2026). Multivalent plain polysaccharide vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/multivalent-plain-polysaccharide-vaccine. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing